Does Rallies show Form 4 insider transactions for APLS?

Yes. Rallies tracks APLS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is APLS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for APLS. It does not provide personalized investment advice.

APLS (Apellis Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Apellis Pharmaceuticals, Inc. Common Stock (APLS) is a publicly traded Healthcare sector company. As of May 21, 2026, APLS trades at $41.03 with a market cap of $5.25B and a P/E ratio of -25.64. APLS moved -0.04% today. Year to date, APLS is +64.32%; over the trailing twelve months it is +137.44%. Its 52-week range spans $16.10 to $41.14. Analyst consensus is neutral with an average price target of $39.50. Rallies surfaces APLS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading APLS stock inside the company?

Recent APLS insider activity includes DeLong Mark Jeffrey sold 368, Baumal Caroline sold 2.80K, Chopas James George sold 2.06K, DeLong Mark Jeffrey sold 3.37K, and Deschatelets Pascal sold 5.93K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

APLS Key Metrics

Key financial metrics for APLS
Metric	Value
Price	$41.03
Market Cap	$5.25B
P/E Ratio	-25.64
EPS	$-1.60
Dividend Yield	0.00%
52-Week High	$41.14
52-Week Low	$16.10
Volume	0
Avg Volume	0
Revenue (TTM)	$781.37M
Net Income	$-197.88M
Gross Margin	0.00%

Recent APLS Insider Trades

DeLong Mark Jeffrey sold 368 (~$8.15K) on Feb 11, 2026.
Baumal Caroline sold 2.80K (~$60.88K) on Jan 22, 2026.
Chopas James George sold 2.06K (~$44.92K) on Jan 22, 2026.
DeLong Mark Jeffrey sold 3.37K (~$73.37K) on Jan 22, 2026.
Deschatelets Pascal sold 5.93K (~$129.03K) on Jan 22, 2026.

Latest APLS News

Biogen Finalizes $5.3B Acquisition of Apellis, Gains $689M Drugs — May 15, 2026
Apellis to Exit S&P SmallCap 600 on May 14 as Q1 EPS Tops Estimates — May 7, 2026
Apellis to Be Acquired by Biogen for $41 Cash and $4 CVR — Apr 20, 2026
Biogen to Buy Apellis for $5.6B at 140% Premium, Adding $689M Revenue — Apr 1, 2026
Apellis Appoints Ex-Pfizer CSO Dolsten to Board, Oversaw 36 Approvals — Mar 2, 2026

APLS Analyst Consensus

18 analysts cover APLS: 0 strong buy, 2 buy, 16 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $39.50.

Common questions about APLS

Who is trading APLS stock inside the company?: Recent APLS insider activity includes DeLong Mark Jeffrey sold 368, Baumal Caroline sold 2.80K, Chopas James George sold 2.06K, DeLong Mark Jeffrey sold 3.37K, and Deschatelets Pascal sold 5.93K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for APLS?: Yes. Rallies tracks APLS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is APLS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for APLS. It does not provide personalized investment advice.